Global Neuroblastoma Drug Market, By Mechanism of Action Type (Alkylating agents, Antimetabolites, Antibiotics, Microtubule Inhibitors, Monoclonal Antibodies), Drug Type (Cyclophosphamide, Cisplatin, Vincristine, Doxorubicin, Etoposide, Topotecan, Busulfan and Melphalan), Diagnosis Type (Physical Test, Urine and Blood Test, Imaging Test, Tissue Sample Testing, Bone Marrow Sample Testing), Treatment Type (Surgery, Chemotherapy, Radiotherapy, Immunotherapy, Bone Marrow transplantation, Retinoid Therapy, Targeted Delivery of Radionuclides), Route of Administration (Oral, Intravenous and others), ), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Neuroblastoma Drug Market
The neuroblastoma drug market is expected to gain market growth at a potential rate of 4% in the forecast period of 2021 to 2028. Rising prevalence of childhood cancer is the vital factor escalating the market growth.
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which ascends from the neuroblasts. The cancer progresses in the nerve tissues of adrenal, chest or spinal cord. In more than 90% of the cases neuroblastoma is diagnosed before the age of 5. In rare cases, the cancer can be spotted in the ultrasounds before birth.
Major factors that are expected to boost the growth of the neuroblastoma drug market in the forecast period are the increasing consciousness towards the diagnosis and the treatment of neuroblastoma cancer, the increasing of incidences of childhood cancers which acts as a catalyst. Furthermore, the growing of birth rate around the globe and the increase in the research on neuroblastoma treatment and the growing expenditure on cancer treatment are the few factors further anticipated to propel the growth of the neuroblastoma drug market. However, the increase in the cost of treatment and the harmful side effects of treatment and the lack of trained healthcare specialists are few of the other factors responsible for the impeding the growth of the neuroblastoma drug market in the near future.
Neuroblastoma drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the neuroblastoma drug market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Neuroblastoma Drug Market Scope and Market Size
The neuroblastoma drug market is segmented on the basis of mechanism of action type, drug type, diagnosis type, treatment type, route of administration and end users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Based on the mechanism of action type, the neuroblastoma drug market is segmented into alkylating agents, antimetabolites, antibiotics, microtubule inhibitors, monoclonal antibodies.
- Based on the drug type, the neuroblastoma drug market is segmented into cyclophosphamide, cisplatin, vincristine, doxorubicin, etoposide, topotecan, busulfan and melphalan.
- Based on the diagnosis type, the neuroblastoma drug market is segmented into physical test, urine and blood test, imaging test, tissue sample testing, bone marrow sample testing.
- Based on the treatment type, the neuroblastoma drug market is segmented into surgery, chemotherapy, radiotherapy, immunotherapy, bone marrow transplantation, retinoid therapy, targeted delivery of radionuclides.
- Based on the route of administration, the neuroblastoma drug market is segmented into oral, intravenous and others.
- Based on the end users, the neuroblastoma drug market is segmented into hospitals, homecare, specialty clinics, others.
Neuroblastoma Drug Market Country Level Analysis
The neuroblastoma drug market is analysed and market size information is provided by country, mechanism of action type, drug type, diagnosis type, treatment type, route of administration and end users as referenced above.
The countries covered in the neuroblastoma drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
The Americas dominates the neuroblastoma drug market because of the well-established healthcare sector. Furthermore, the increasing occurrences of childhood cancer will further boost the growth of the neuroblastoma drug market in the region during the forecast period. Asia Pacific is projected to observe significant amount of growth in the neuroblastoma drug market because of the vast patient population of childhood cancer. Moreover, the growing development of hospitals for childhood cancer treatment is further anticipated to propel the growth of the neuroblastoma drug market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The neuroblastoma drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Neuroblastoma Drug Market Share Analysis
The neuroblastoma drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to neuroblastoma drug market.
The major players covered in the neuroblastoma drug market report are CELLECTAR BIOSCIENCES, INC, United Therapeutics Corporation, APEIRON Biologics AG., Baxter, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bayer AG, MacroGenics, Inc., Advaxis Inc., Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Curis, Inc., Lilly, GlaxoSmithKline plc., Marsala Biotech Inc., Merck KGaA, Merck & Co., Inc, Oncolytics Biotech, Inc., ONO PHARMACEUTICAL CO., LTD., Pfizer Inc., Pierre Fabre Group, Cyclacel Pharmaceuticals, Inc., BioDiem, among other domestic and global players. Regenerative medicine market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-